MaxCyte Inc (MXCT) has released an update to notify the public and investors about its officers.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cenk Sumen, Ph.D., concluded his role as Chief Scientific Officer of MaxCyte, Inc. on January 23, 2024. Per his Severance Agreement, he will receive his base salary for nine months post-termination and health care continuation contributions. These benefits depend on his adherence to a release of claims agreement. Dr. Sumen will continue his association with MaxCyte as a member of the Scientific Advisory Board.
For further insights into MXCT corporate activity, check out TipRanks’ Insiders Trading Activity page.
